Natera Inc. NTRA said Japan’s Ministry of Health, Labour and Welfare approved its Signatera molecular residual disease (MRD) test for patients with colorectal cancer in the adjuvant setting, making it ...

Natera reported new data from the ESMO 2026 Congress and ASN Kidney Week, highlighting Signatera’s ctDNA assays across ...

COLORADO SPRINGS, Colo. (KKTV) - A southern Colorado man is sharing how a blood test helped him catch his second cancer diagnosis. The test is called Signatera, and the FDA recently approved it for ...

Natera, Inc. is a diagnostic company focusing on cfDNA tests in women's health, organ health, and oncology. Natera's MRD test, Signatera, demonstrated strong growth, with a 64% increase in processed ...

Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study Signatera outperformed AMERK, the current standard of care for prognosis and ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that its personalized and tumor-informed molecular residual disease (MRD) test, ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new data in JAMA Oncology, evaluating the utility of Signatera, its ...

Natera Inc. (NASDAQ: NTRA) announced positive results from the phase III IMvigor011 clinical trial for muscle-invasive bladder cancer, which used the company's Signatera circulating tumor DNA test to ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the activation of the NRG Oncology trial, ARCHER (NRG-GU015), a ...

Natera's third-quarter 2026 results hinge on Signatera volume growth, regulatory milestones and higher test prices, while ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its Signatera molecular residual disease (MRD) test has been named to TIME’s Best Inventions ...

Randomized study aims to reduce treatment burden for patients and utilizes Signatera to monitor for disease recurrence AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global ...